Fortis Malar (523696)
Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹65.66 |
| Market Cap | ₹123.06 Cr |
| P/E Ratio | 22.32 |
| ROCE | 0.83% |
| ROE | 15.53% |
| Dividend Yield | 0% |
| Profit Growth | 100% |
| Debt/Equity | — |
| Sales Growth | 0% |
| 52-Week Range | ₹40.75 — ₹69 |
| Sector | Healthcare Services |
| Book Value | ₹16.43 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
As an investor, I like businesses that are simple, earn solid returns on tangible capital, and give me a margin of safety. Fortis Malar is a hospital, and I can understand that business. But the numbers here do not make me eager to pay ₹65.66. Book value is only ₹16.43, so the market is asking 4 times book. Return on equity is 15.53%, which is respectable, but return on capital employed is just 0.83%. That tells me equity returns may not be coming from a strong core franchise—or the capital base is too heavy relative to operating profits. Either way, it is not the kind of economics I look for. Sales growth is zero. Zero. The latest quarter shows ₹0 sales and ₹0 net profit. I cannot value a business on a blank quarter unless there is a clear, honest explanation. The reported 100% profit growth and PEG of 0.22 are tempting, but growth on stagnant revenue is usually arithmetic, not a durable moat. If revenue does not grow, profits cannot compound for long. There is no dividend, so the shareholder depends entirely on price change; that makes valuation discipline even more important. At 22.32 times earnings, I am being asked to pay up for no growth, nil dividend, negligible ROCE, and missing data on promoter holding. A Piotroski score of 6/9 is a mild positive, but it does not compensate for the lack of economic momentum. The 52-week range of ₹40.75 to ₹76.00 tells me the market itself has been uncertain. In my view this is closer to a slow grower or special situation, not a predictable compounding machine. Until I see real revenue, tangible returns on capital, and some indication of governance, I would keep this on the watchlist, not in the portfolio.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer